查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832217

抗病毒藥物市場（按適應症、藥物類別、給藥途徑、分銷管道和最終用戶分類）—2025-2032 年全球預測

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年抗病毒藥物市場規模將成長至 1,008.3 億美元，複合年成長率為 6.73%。

主要市場統計數據
預測年份（2024年） 598.4億美元
基準年（2025年） 638.1億美元
預測年份（2032年） 1008.3億美元
複合年成長率（%） 6.73%

簡明介紹當前抗病毒治療領域，整合科學進步、臨床壓力和對策略領導者的系統性影響

抗病毒領域正處於曲折點，治療創新、醫療服務模式的轉變以及不斷變化的監管環境交織在一起，重塑研發和商業性模式。本執行摘要按適應症、藥物類別和分銷管道總結了最重要的趨勢，並將這些趨勢轉化為對臨床團隊、商業領導者和供應鏈高管的策略啟示。我們的目標是將複雜的跨學科資料濃縮成一份可操作的演示文稿，供那些需要平衡短期業務重點和長期研發路徑的領導者參考。

為了確保與各相關人員群體的相關性，本分析重點關注臨床未滿足需求、技術可行性以及系統壓力，這些因素正在重新定義抗病毒療法的開發和交付方式。分析整合了科學發展軌跡（例如抗病毒治療方法和診斷技術的進步）與實際考慮（例如採購方法、付款人參與度和門診治療實用化）。自始至終，分析都著重於影響患者可及性、治療價值以及應對供應中斷的韌性的決策，為規劃和投資決策提供簡明而細緻的方向。

深入分析從根本上改變抗病毒藥物開發和商業化軌蹟的科學、監管和供應創新

變革性轉變正在改變抗病毒藥物研發和給藥領域的競爭格局和臨床前景。生物和核酸技術正從概念驗證轉向有效的治療策略，推動著旨在延長緩解持續時間、提高依從性和針對機制介入的計畫。同時，診斷技術正在與治療技術融合，從而實現早期檢測和「檢測即治療」模式，這正在影響臨床試驗設計和商業性獲取策略。

監管途徑正在調整，以適應高需求領域的加速發展，支付方也擴大將報銷與現實世界的療效和健康經濟價值掛鉤。數位健康工具正在整合到病患監測和依從性計劃中，支持分散式護理模式，並在臨床適用的情況下將藥物使用從住院環境中轉移出去。靈活的生技藥品產能和模組化製造技術等製造創新正在縮短前置作業時間，並實現在地化供應鏈。總的來說，這些轉變正在創造一種新格局，敏捷性、跨部門夥伴關係和快速的證據生成將決定誰能將科學前景轉化為持續的臨床和商業性成功。

全面評估2025 年美國關稅改革如何為供應鏈彈性和製造在地化帶來直接的採購壓力和策略誘因。

美國關稅調整將於2025年生效，其累積效應將對參與抗病毒治療的機構的採購、製造和臨床運作帶來多方面壓力。對關鍵化學中間體和某些成品徵收的進口關稅將增加依賴全球供應網路的公司的到岸成本，促使採購團隊重新評估籌資策略，並考慮近岸外包或合格的替代供應商以保持連續性。這種向供應商多元化的轉變通常需要大量的前置作業時間和資本投入，以確保獲得替代製造合作夥伴的資格並確保符合監管品質標準。

診所和醫院系統面臨採購價格波動加劇的問題，這會影響其採購週期和庫存政策。一些醫療機構正在擴大庫存緩衝，而另一些機構則正在協商長期採購協議以緩解波動。對開發商而言，關稅帶來的成本壓力可能會改變其在何處以及如何擴大生產規模的考量，儘管本地營運成本較高，但受跨境關稅影響較小的區域生產基地可能會受到青睞。關稅也會影響合約製造機構的動態，因為對合格國內或區域產能的需求增加會在交付時間和定價方面帶來競爭壓力。

新興的政策因應措施和私部門為抵銷影響而採取的策略包括：有針對性的供應協議、加強垂直整合以及關鍵活性藥物原料藥的策略性儲備。這些調整對下游領域也產生了影響，例如臨床試驗材料的供應速度、與付款方和採購方進行價格談判的成本基礎，以及優先考慮那些不需要更複雜投入的治療方案。整體而言，關稅環境正在加速向供應鏈彈性和冗餘度的策略轉變，同時也凸顯了透過流程創新和提高製造效率來控制成本的重要性。

擁有有效策略的公司：對適應症、治療層級、給藥途徑、分銷管道和最終用戶動態的詳細細分洞察推動了差異化策略

根據適應症，我們揭示了針對B肝、C肝、單純皰疹病毒、愛滋病毒、流感病毒和呼吸道症候群病毒的臨床需求和商業策略的差異化途徑。乙肝計畫越來越注重持續的病毒抑制和功能性治癒策略，以推動長期安全性和生物標記的開發；而丙肝計畫則強調便捷的治療方案和可及性模式，以支持廣泛的病例檢測。單純皰疹病毒的管理仍然著重於高風險族群的發病控制和預防；愛滋病毒研究則在長效製劑、以治癒為導向的治療方法與成熟的慢性病照護模式之間尋求平衡。流感和呼吸道融合細胞病毒計畫優先考慮季節性治療和快速診斷，以最佳化治療和預防的時機。

以藥物類別分類，優先考慮的藥物包括融合抑制劑、整合酶抑制劑、非核苷類逆轉錄酶抑制劑、核苷類似物和蛋白酶抑制劑。整合酶抑制劑和融合抑制劑因其新穎的抗藥性特性和優異的耐受性而備受關注，而核苷類似物和蛋白酶抑制劑仍然是成熟方案的基石，需要謹慎的生命週期管理。非核苷類逆轉錄酶抑制劑仍在接受評估，以改善其安全性，並探索聯合用藥策略，從而提高藥物的持久性和依從性。

給藥途徑—吸入、注射、口服和外用—決定了病患的依從性、配送物流和臨床環境。口服療法仍然是門診病人管理和慢性病維持的核心，注射劑和長效製劑有助於提高依從性並減少就診頻率，吸入療法可為呼吸道病毒提供靶向肺部暴露，而局部製劑仍然適用於粘膜皮膚感染疾病，因為局部給藥可提高耐受性。

診所、醫院藥局、線上藥局和零售藥局之間的分銷管道動態影響著藥物的可及性、報銷途徑和即時護理決策。診所和醫院藥局通常提供複雜的治療方案和腸外用藥，而線上藥局和零售藥局則提供更方便的口服和局部製劑。最後，終端使用者細分（包括診所、居家醫療、醫院和長期照護機構）凸顯了照護環境在治療方法選擇中的重要性。居家醫療和門診診所正在推動對易於使用的製劑和簡化監測方案的需求，而醫院和長期護理機構則需要強大的供應和管理工作流程來應對複雜的治療方案。

戰略區域見解強調監管、臨床和製造因素如何影響美洲、歐洲、中東和非洲以及亞太地區的實施選擇

區域動態對於確定抗病毒藥物研發重點、生產地點和商業化方案至關重要。在美洲，成熟的研究基礎設施和廣泛的臨床試驗網路支持快速的轉化活動，而政策辯論和付款人框架則影響定價策略和可及性模式。美洲也是長效和先進治療方法上市的關鍵市場，其醫療保健體系能夠適應複雜的基於價值的協議和上市後證據收集。

歐洲、中東和非洲地區環境複雜，監管協調力道不足，報銷格局也各異。歐洲法規結構強調穩健的比較有效性和健康經濟證據，鼓勵製造商在研發早期就投資於真實世界數據收集和支付方參與。中東和非洲地區在藥品可及性方面面臨獨特的挑戰，也為官民合作關係提供了機遇，重點是建立生產能力和分銷網路，以覆蓋服務不足的人群。

亞太地區是一個多元化的地區，擁有快速成長的研發投入、龐大的病患群體和顯著的未滿足需求，以及新興的生產能力。亞太地區的多個經濟體正在大力投資小分子和生技藥品的生產，優惠的政策獎勵也正在加速臨床開發吞吐量。該地區的商業策略必須協調多元化的支付系統、波動的患者負擔能力，以及數位管道在患者參與和分銷中日益增強的作用。任何地區成功的計畫都必須將證據產生、供應鏈設計和商業模式與當地監管期望和醫療保健服務的實際情況相結合。

從公司層級對創新、製造策略和夥伴關係模式的實用觀點，推動抗病毒藥物開發和商業化的競爭優勢

抗病毒治療領域的企業策略正圍繞著幾個影響深遠的優先事項展開，包括推動差異化治療方法、確保韌性生產能力以及在整個生態系統中建立合作夥伴關係。領先的開發商正在平衡內部創新與標靶授權合約和共同開發契約，以加速獲取新機制並管理技術風險。投資能夠以模組化方式調整病毒標靶的平台技術，可以加快從藥物發現到臨床候選藥物的轉化，各公司越來越優先考慮那些能夠明確提高依從性並減少密集監測需求的資產。

在營運方面，企業正在不斷整合其供應鏈，透過選擇性垂直遷移和策略製造聯盟來擴大產能，並降低跨境成本衝擊的風險。在商業方面，他們正在試驗基於價值的合約和付款人合作夥伴關係，以使長期成果與報銷結構保持一致，而專業的商業化團隊則專注於差異化管道，例如醫院處方集和專科藥房。同時，大型跨國製藥公司擁有規模優勢、監管專業知識以及全球分銷網路的管道。對於所有類型的公司而言，成功越來越取決於其能否將臨床差異化展現為患者和系統價值，並透過複雜的護理路徑將這種價值實用化。

針對研發優先事項、製造彈性、付款人參與度和商業性執行提出具體、優先的建議，以確保持續的抗病毒藥物成功

產業領導者應優先考慮一系列切實可行的措施，使研發選擇與商業性執行和供應鏈韌性相協調。首先，加快對長效、有針對性的給藥方式的投資，這些方式能夠顯著提高依從性並減輕系統負擔，並將臨床開發計劃與收集真實世界證據以支持報銷的穩健計劃相結合。其次，透過確保區域合作夥伴和靈活的製造外包實現生產佈局多元化，並結合針對關稅中斷和投入短缺的情境規劃，最大限度地降低臨床試驗和商業供應的風險。

第三，制定整合診斷和遠端醫療途徑的上市策略，以快速識別合格治療條件的患者，並減少開始治療的障礙。第四，儘早與付款方溝通，明確證據要求，並探索基於結果的、風險共擔和回報共用的報銷結構。第五，建立策略聯盟，將平台技術與商業化專業知識結合，例如透過共同開發、授權或有針對性的收購來填補能力缺口。第六，投資數位化病患援助項目，以提高服藥依從性，取得結果數據，並降低醫療保健總成本。最後，將永續性納入採購和製造決策，以減少地緣政治和關稅壓力的影響，同時滿足相關人員對韌性和負責任的企業營運日益成長的期望。

對多方法調查方法的透明解釋，該方法結合了專家訪談、監管和科學評論以及情境分析，以檢驗可行的見解

本執行摘要所依據的研究採用多方法論，結合專家的初步研究、二手文獻、監管備案文件和技術資料來源，以提供全面且檢驗的見解。初步意見包括與臨床實驗研究人員、供應鏈經理、監管專家和商業行業領袖進行的結構化訪談，以提供有關營運挑戰、臨床重點和付款人期望的底層觀點。二次審查涵蓋同儕審查文獻、臨床試驗註冊中心、專利態勢和官方監管決策，以繪製科學趨勢和開發平臺。

分析方法包括定性主題綜合（用於識別重複出現的策略主題）、比較政策分析（用於確定各地區法規的影響）以及情境規劃（用於評估供應鏈和關稅的影響）。品質保證透過以下方式實現：透過文件檢驗對訪談結果進行交叉驗證，並將中期主題提交給獨立專家小組徵求回饋。調查方法認知到水平掃描和專家訪談的固有局限性，包括受訪者抽樣偏差的可能性以及臨床研究的快速發展性。這些限制透過多元化的利害關係人相關人員和反覆的檢驗週期相關人員。由此得出的洞察優先考慮穩健性和實際相關性，以幫助決策者將短期營運需求與長期檢驗目標結合。

最終整合關鍵策略重點，將抗病毒治療的科學前景轉化為持續的臨床和商業性成功

總而言之，抗病毒療法正經歷一個由技術發展勢頭、供應鏈複雜性不斷增加以及市場准入要求不斷演變的時期。科學進步為透過長效藥物和標靶治療方法改善患者預後提供了清晰的途徑，但成功將取決於自適應製造策略、整合診斷和成熟的支付方參與。區域監管預期和關稅驅動的供應動態交互作用凸顯了本地化執行和穩健應急計劃的重要性。

那些將臨床開發與實踐價值驗證相結合、實現生產和採購方式多樣化、並投資於數位化工具以提升依從性和證據採集的開發領導者，將最有能力將科學潛力轉化為可及的治療方法。本摘要中的建議旨在指南當前的營運決策，同時支援長期投資以建立持續的競爭優勢。那些兼具戰術性反應和戰略遠見的組織將能夠緩解短期干擾，並在不斷變化的抗病毒領域中釋放永續的成長機會。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 迅速以長效注射抗病毒療法預防及治療愛滋病毒
  • 在資源有限的地區擴大丙型肝炎的直接抗病毒治療
  • 針對保守病毒聚合酵素和蛋白酶的廣譜頻譜抗病毒藥物的開發
  • 在高風險兒科族群中傳播針對呼吸道融合病毒（RSV）的單株抗體預防
  • 將人工智慧和機器學習融入抗病毒藥物研發和再利用工作
  • 聯合抗病毒療法的出現，對抗藥性流感病毒株的療效增強
  • 為了應對疫情，我們正在加大對整體冠狀病毒治療平台的投資。

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第 8 章：抗病毒藥物市場（按適應症）

  • B型肝炎
  • C型肝炎
  • 單純皰疹
  • HIV
  • 流感
  • 呼吸道融合病毒（RSV）

9. 抗病毒藥物市場（依藥物類別）

  • 融合抑制劑
  • 整合酶抑制劑
  • 非核苷逆轉錄酶抑制劑
  • 核苷類似物
  • 蛋白酶抑制劑

第10章抗病毒藥物市場（依給藥途徑）

  • 吸入
  • 注射
  • 口服
  • 外用

第 11 章抗病毒藥物市場（按分銷管道）

  • 診所
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 12 章。抗病毒藥物市場（按最終用戶）

  • 診所
  • 居家醫療
  • 醫院
  • 長期照護機構

第 13 章：抗病毒藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗病毒藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國抗病毒藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • ViiV Healthcare Limited
    • AstraZeneca plc
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market is projected to grow by USD 100.83 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 59.84 billion
Estimated Year [2025] USD 63.81 billion
Forecast Year [2032] USD 100.83 billion
CAGR (%) 6.73%

Concise orientation to the current antiviral therapeutics landscape that synthesizes scientific advances, clinical pressures, and system implications for strategic leaders

The antiviral drugs landscape is at an inflection point where therapeutic innovation, shifting care delivery models, and evolving regulatory expectations intersect to reshape research, development, and commercial approaches. This executive summary synthesizes the most consequential developments across indications, drug classes, and distribution channels, and it translates those developments into strategic implications for clinical teams, commercial leaders, and supply chain executives. The goal is to present an actionable condensation of complex, cross-disciplinary data for leaders who must balance near-term operational priorities with longer-term R&D pathways.

To ensure relevance across stakeholder groups, the analysis foregrounds clinical unmet needs, technology enablers, and system pressures that are redefining how antiviral therapies are developed and delivered. The narrative integrates scientific trajectories-such as advances in antiviral modalities and diagnostics-with practical considerations including procurement practices, payer engagement, and the operationalization of outpatient care. Throughout, emphasis is placed on decisions that influence patient access, therapeutic value, and resilience against supply disruptions, providing a concise yet nuanced orientation for planning and investment decisions.

Detailed analysis of the converging scientific, regulatory, and delivery innovations that are fundamentally reshaping development and commercialization pathways for antivirals

A number of transformative shifts are altering the competitive and clinical contours of antiviral therapy development and delivery. Biologic modalities and nucleic acid technologies have moved from proof-of-concept stages into validated therapeutic strategies, fueling programs that aim to deliver longer duration of effect, improved adherence, and targeted mechanism-based interventions. Concurrently, diagnostics are converging with therapeutics to enable earlier detection and test-and-treat paradigms, which in turn influence clinical trial design and commercial access strategies.

Regulatory pathways have adjusted to accommodate accelerated development in high-need areas, and payers are increasingly tying reimbursement to demonstrable real-world outcomes and health economic value. Digital health tools are being integrated into patient monitoring and adherence programs, supporting decentralized care models and shifting utilization away from inpatient settings when clinically appropriate. Manufacturing innovation, including flexible biologics capacity and modular production techniques, is reducing lead times and enabling regionalized supply chains. These shifts collectively create a landscape in which agility, cross-sector partnerships, and rapid evidence generation determine who can translate scientific promise into durable clinical and commercial success.

Comprehensive assessment of how the 2025 United States tariff changes create immediate procurement pressures and strategic incentives for supply chain resilience and manufacturing localization

The cumulative effect of the United States tariff adjustments enacted in 2025 introduces multifaceted pressures across procurement, manufacturing, and clinical operations for organizations engaged in antiviral therapeutics. Import duties on key chemical intermediates and selected finished pharmaceuticals have increased landed costs for firms that rely on global supply networks, prompting procurement teams to reassess sourcing strategies and to explore nearshoring or alternate supplier qualification to maintain continuity. This reorientation toward supplier diversification often requires significant lead time and capital investment to qualify alternate manufacturing partners and to ensure compliance with regulatory quality standards.

Clinics and hospital systems face increased variability in procurement pricing, which in turn affects purchasing cycles and inventory policies; some institutions are extending inventory buffers while others are negotiating longer term purchasing agreements to mitigate volatility. For developers, tariff-driven cost pressures can change the calculus for where and how manufacturing scale-up is executed, potentially favoring regional production hubs that reduce exposure to cross-border duties despite higher local operating costs. The tariffs also influence the dynamics of contract manufacturing organizations, as increased demand for domestic or qualified regional capacity creates competitive pressure on timelines and pricing.

Policy responses and private sector strategies are emerging to offset impacts, including targeted supply agreements, increased vertical integration, and strategic stockpiling for critical active pharmaceutical ingredients. These adjustments have downstream effects on the speed of clinical trial material provisioning, the cost base for pricing negotiations with payers and procurers, and the prioritization of therapeutic pipelines that require fewer complex inputs. In aggregate, the tariff environment accelerates a strategic shift toward resilience and redundancy in supply chains while elevating the importance of cost containment through process innovation and manufacturing efficiency.

In-depth segmentation insights spanning indications, therapeutic classes, administration routes, distribution channels, and end-user dynamics driving differentiated strategies

Segmentation by indication reveals differentiated pathways of clinical need and commercial strategy across Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, and Respiratory Syncytial Virus. Hepatitis B programs are increasingly focused on durable viral suppression and functional cure strategies, demanding long-term safety and biomarker development, whereas Hepatitis C efforts emphasize simplified regimens and access models that support broad case finding. Herpes Simplex management remains concentrated on episodic control and prophylaxis for high-risk populations, while HIV research balances long-acting formulations and cure-directed approaches alongside established chronic care models. Influenza and Respiratory Syncytial Virus programs prioritize seasonally responsive therapies and rapid diagnostics to optimize timing of treatment and prophylaxis.

When viewed by drug class, priorities vary between Fusion Inhibitors, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogues, and Protease Inhibitors. Integrase and fusion inhibitors are attracting interest for novel resistance profiles and tolerability advantages, while nucleoside analogues and protease inhibitors remain foundational for established regimens that require careful lifecycle management. Non-Nucleoside Reverse Transcriptase Inhibitors continue to be evaluated for improved safety profiles and combination strategies that enhance durability and adherence.

Routes of administration, spanning inhalation, injectable, oral, and topical, shape patient adherence, distribution logistics, and clinical setting. Oral therapies remain central for outpatient management and chronic disease maintenance, injectables and long-acting formulations support adherence and reduce clinic visit frequency, inhalation therapeutics offer targeted pulmonary exposure for respiratory viruses, and topical formulations maintain relevance for mucocutaneous infections where localized delivery improves tolerability.

Distribution channel dynamics across clinics, hospital pharmacies, online pharmacies, and retail pharmacies influence access, reimbursement pathways, and point-of-care decisioning. Clinics and hospital pharmacies often handle complex regimens and parenteral products supported by institutional procurement processes, while online and retail pharmacies expand reach and convenience for oral and topical therapies. Finally, end user segmentation that includes clinics, home care, hospitals, and long term care facilities highlights the importance of care setting in therapeutic choice, with home care and outpatient clinics driving demand for user-friendly formulations and simplified monitoring protocols, and hospitals and long term care facilities requiring robust supply and administration workflows for complex regimens.

Strategic regional considerations highlighting how distinct regulatory, clinical, and manufacturing factors in the Americas, Europe Middle East & Africa, and Asia-Pacific shape execution choices

Regional dynamics are central to shaping R&D priorities, manufacturing placement, and commercialization approaches across the antiviral landscape. In the Americas, established research infrastructure and widespread clinical trial networks support rapid translational efforts, while policy debates and payer frameworks influence pricing strategies and access models. The Americas also function as a key market for long-acting and advanced modality launches, with healthcare systems that can absorb complex value-based contracting and post-launch evidence collection.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with varied reimbursement landscapes. European regulatory frameworks favor robust comparative effectiveness and health economic evidence, motivating manufacturers to invest in real-world data generation and payer engagement early in development. The Middle East & Africa region presents distinct access challenges and opportunities for public-private partnerships focused on manufacturing capacity building and distribution networks that reach underserved populations.

Asia-Pacific is a diverse region that combines rapidly expanding R&D investment, large patient populations with significant unmet needs, and emerging manufacturing prowess. Several economies within Asia-Pacific are investing heavily in both small molecule and biologics manufacturing, and favorable policy incentives are accelerating clinical development throughput. Commercial strategies in the region must reconcile heterogenous payer systems, variable patient affordability, and the increasing role of digital channels for patient engagement and distribution. Across all regions, successful programs are those that tailor evidence generation, supply chain design, and commercial models to local regulatory expectations and care delivery realities.

Practical company-level perspectives on innovation, manufacturing strategy, and partnership models that are driving competitive advantage in antiviral development and commercialization

Company strategies in antiviral therapeutics are converging on a few high-impact priorities: advancing differentiated modalities, securing resilient manufacturing capacity, and forging collaborative partnerships across the ecosystem. Leading developers are balancing in-house innovation with targeted licensing and co-development agreements that accelerate access to novel mechanisms while managing technical risk. Investment in platform technologies that enable modular adaptation across viral targets is enabling faster transition from discovery to clinical candidate, and companies are increasingly prioritizing assets with clear pathways to improved adherence or reduced need for intensive monitoring.

Operationally, firms are bolstering supply chain integration and expanding capacity through selective vertical moves or strategic manufacturing partnerships to reduce exposure to cross-border cost shocks. Commercially, organizations are experimenting with value-based contracting and payer partnerships that align long-term outcomes with reimbursement structures, while specialist commercialization teams focus on differentiated channels such as hospital formularies and specialty pharmacies. Smaller biotech firms are leveraging nimble development processes and focused proof-of-concept studies to attract partnerships, while larger multinational pharmaceutical companies provide scale, regulatory expertise, and access to global distribution networks. Across company types, success increasingly depends on the ability to translate clinical differentiation into demonstrable patient and system value and to operationalize that value across complex care pathways.

Concrete and prioritized recommendations for R&D prioritization, manufacturing resilience, payer engagement, and commercial execution to drive durable success in antivirals

Industry leaders should prioritize a suite of actionable measures that align R&D choices with commercial execution and supply chain resilience. First, accelerate investment in long-acting and targeted delivery modalities that demonstrably improve adherence and reduce system burden, pairing clinical development plans with robust plans for real-world evidence collection to support reimbursement. Second, diversify manufacturing footprints by qualifying regional partners and flexible contract manufacturers, and incorporate scenario planning for tariff-driven disruptions and input scarcity to minimize risks to clinical trials and commercial supply.

Third, design launch strategies that integrate diagnostics and telehealth pathways, enabling rapid identification of treatment-eligible patients and reducing barriers to initiation. Fourth, engage payers early to define evidence requirements and to explore outcome-based reimbursement structures that share risk and reward. Fifth, cultivate strategic alliances that pair platform technologies with commercialization expertise, whether through co-development, licensing, or targeted acquisitions that fill capability gaps. Sixth, invest in digital and patient support programs that improve adherence, collect outcome data, and reduce the total cost of care. Finally, embed sustainability into procurement and manufacturing decisions to reduce exposure to geopolitical and tariff pressures while meeting growing stakeholder expectations for resilient and responsible operations.

Transparent description of the multi-method research approach combining expert interviews, regulatory and scientific review, and scenario analysis to validate actionable insights

The research underpinning this executive summary draws on a multi-method approach that triangulates primary expert interviews, secondary literature, regulatory filings, and technical data sources to ensure comprehensive and validated insights. Primary inputs included structured interviews with clinical investigators, supply chain managers, regulatory experts, and commercial leaders, providing ground-level perspectives on operational challenges, clinical priorities, and payer expectations. Secondary review encompassed peer-reviewed literature, clinical trial registries, patent landscapes, and public regulatory decisions to map scientific trends and development pipelines.

Analytical methods included qualitative thematic synthesis to identify recurrent strategic themes, comparative policy analysis to discern regional regulatory implications, and scenario planning to evaluate supply chain and tariff impacts. Quality assurance was maintained through cross-validation of interview findings with document review and by presenting interim themes to an independent panel of subject matter experts for feedback. The methodology acknowledges limitations inherent to horizon scanning and expert elicitation, including potential sampling bias in interview subjects and the rapidly evolving nature of clinical research; these limitations were mitigated through diverse stakeholder engagement and repeated validation cycles. The resulting insights prioritize robustness and practical relevance for decision makers seeking to align near-term operational imperatives with longer-term strategic objectives.

Final synthesis of the critical strategic priorities for converting scientific promise into durable clinical and commercial success in antiviral therapeutics

In summation, antiviral therapeutics are entering a period defined by technological momentum, heightened supply chain complexity, and evolving market access requirements. Scientific advances provide clear pathways to improved patient outcomes through longer-acting agents and targeted modalities, yet successful translation depends on adaptive manufacturing strategies, integrated diagnostics, and sophisticated payer engagement. The interplay of regional regulatory expectations and tariff-driven supply dynamics underscores the importance of localized execution and robust contingency planning.

Leaders who align clinical development with pragmatic proofs of value, diversify manufacturing and procurement approaches, and invest in digital tools for adherence and evidence capture will be best positioned to convert scientific potential into accessible therapies. The recommendations contained in this summary are intended to guide immediate operational decisions while supporting longer-term investments that build durable competitive advantage. Organizations that act with both tactical responsiveness and strategic foresight can mitigate near-term disruptions and unlock sustainable growth opportunities in the evolving antiviral landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of long-acting injectable antiviral therapies for HIV prevention and treatment
  • 5.2. Expansion of direct-acting antiviral regimens for hepatitis C in resource-limited settings
  • 5.3. Development of broad-spectrum antiviral agents targeting conserved viral polymerases and proteases
  • 5.4. Growth of monoclonal antibody prophylactics for respiratory syncytial virus in high-risk pediatric populations
  • 5.5. Integration of artificial intelligence and machine learning in antiviral drug discovery and repurposing efforts
  • 5.6. Emergence of combination antiviral therapies enhancing potency against drug-resistant influenza strains
  • 5.7. Increased investment in pan-coronavirus therapeutic platforms for pandemic preparedness

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs Market, by Indication

  • 8.1. Hepatitis B
  • 8.2. Hepatitis C
  • 8.3. Herpes Simplex
  • 8.4. Hiv
  • 8.5. Influenza
  • 8.6. Respiratory Syncytial Virus

9. Antiviral Drugs Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Non Nucleoside Reverse Transcriptase Inhibitors
  • 9.4. Nucleoside Analogues
  • 9.5. Protease Inhibitors

10. Antiviral Drugs Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Drugs Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Antiviral Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Long Term Care Facilities

13. Antiviral Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. AbbVie Inc.
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. GlaxoSmithKline plc
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. ViiV Healthcare Limited
    • 16.3.10. AstraZeneca plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 338. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTI